Literature DB >> 18155955

Lack of genotoxic effects in hematopoietic and gastrointestinal cells of mice receiving chromium(VI) with the drinking water.

Silvio De Flora1, Francesco D'Agostini, Roumen Balansky, Rosanna Micale, Barbara Baluce, Alberto Izzotti.   

Abstract

Chromium(VI) is genotoxic when tested in vitro or injected parenterally in such a way to escape detoxification mechanisms. However, its genotoxicity and potential carcinogenicity are lost, depending on dose and administration route, due to efficient reduction in body fluids and nontarget cells. Chromium(VI) is a Group 1 IARC carcinogen, but only in the respiratory tract and in well-defined occupational settings that involved heavy exposures. Recently, concern has been expressed that oral chromium(VI) may be a gastric carcinogen. We demonstrated that administration of very high doses of chromium(VI) with the drinking water does not induce any clastogenic effect in hematopoietic cells of adult mice and their fetuses. Thereafter, we investigated whether administration of chromium(VI) with the drinking water may induce local genotoxic effects in the gastrointestinal tract. Sodium dichromate dihydrate was administered to mice for 9 consecutive months, at doses corresponding to 5 and 20 mg chromium(VI)/l, which exceed drinking water standards by 100 and 400 times, respectively. Under these conditions, chromium(VI) failed to enhance the frequency of DNA-protein crosslinks and did not cause oxidative DNA damage, measured in terms of 8-oxo-2'-deoxyguanosine, in the forestomach, glandular stomach and duodenum. When cells from the same organs were isolated and challenged in vitro with chromium(VI), as positive controls, the same genotoxicity biomarkers were evidently affected. Thus, consistently with the knowledge accumulated in 50 years of research on chromium(VI) kinetics and metabolism, oral chromium(VI) appears to be devoid of genotoxicity in the gastrointestinal tract. After 9 months, we did not observe any variation of tumor yield in skin, lung, forestomach, glandular stomach, and duodenum of chromium(VI)-treated mice. These results are discussed in the light of literature data, also including a recent 2-year carcinogenicity study performed by the National Toxicology Program.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18155955     DOI: 10.1016/j.mrrev.2007.11.005

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  13 in total

1.  Exposure to hexavalent chromium resulted in significantly higher tissue chromium burden compared with trivalent chromium following similar oral doses to male F344/N rats and female B6C3F1 mice.

Authors:  Bradley J Collins; Matthew D Stout; Keith E Levine; Grace E Kissling; Ronald L Melnick; Timothy R Fennell; Ramsey Walden; Kamal Abdo; John B Pritchard; Reshan A Fernando; Leo T Burka; Michelle J Hooth
Journal:  Toxicol Sci       Date:  2010-09-15       Impact factor: 4.849

Review 2.  Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans.

Authors:  Chad M Thompson; Deborah M Proctor; Mina Suh; Laurie C Haws; Christopher R Kirman; Mark A Harris
Journal:  Crit Rev Toxicol       Date:  2013-03       Impact factor: 5.635

Review 3.  Oral Chromium Exposure and Toxicity.

Authors:  Hong Sun; Jason Brocato; Max Costa
Journal:  Curr Environ Health Rep       Date:  2015-09

Review 4.  Application of the U.S. EPA mode of action Framework for purposes of guiding future research: a case study involving the oral carcinogenicity of hexavalent chromium.

Authors:  Chad M Thompson; Laurie C Haws; Mark A Harris; Nicole M Gatto; Deborah M Proctor
Journal:  Toxicol Sci       Date:  2010-10-14       Impact factor: 4.849

Review 5.  Chromium in drinking water: sources, metabolism, and cancer risks.

Authors:  Anatoly Zhitkovich
Journal:  Chem Res Toxicol       Date:  2011-07-28       Impact factor: 3.739

6.  Investigation of the mode of action underlying the tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium.

Authors:  Chad M Thompson; Deborah M Proctor; Laurie C Haws; Charles D Hébert; Sheila D Grimes; Howard G Shertzer; Anna K Kopec; J Gregory Hixon; Timothy R Zacharewski; Mark A Harris
Journal:  Toxicol Sci       Date:  2011-06-28       Impact factor: 4.849

7.  Hexavalent chromium is carcinogenic to F344/N rats and B6C3F1 mice after chronic oral exposure.

Authors:  Matthew D Stout; Ronald A Herbert; Grace E Kissling; Bradley J Collins; Gregory S Travlos; Kristine L Witt; Ronald L Melnick; Kamal M Abdo; David E Malarkey; Michelle J Hooth
Journal:  Environ Health Perspect       Date:  2008-12-31       Impact factor: 9.031

8.  Assessment of Cr(VI)-induced cytotoxicity and genotoxicity using high content analysis.

Authors:  Chad M Thompson; Yuriy Fedorov; Daniel D Brown; Mina Suh; Deborah M Proctor; Liz Kuriakose; Laurie C Haws; Mark A Harris
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

9.  Determination of metal ion content of beverages and estimation of target hazard quotients: a comparative study.

Authors:  Theresa Hague; Andrea Petroczi; Paul L R Andrews; James Barker; Declan P Naughton
Journal:  Chem Cent J       Date:  2008-06-25       Impact factor: 4.215

10.  Comparison of Toxicity and Recovery in the Duodenum of B6C3F1 Mice Following Treatment with Intestinal Carcinogens Captan, Folpet, and Hexavalent Chromium.

Authors:  Chad M Thompson; Jeffrey C Wolf; Alene McCoy; Mina Suh; Deborah M Proctor; Christopher R Kirman; Laurie C Haws; Mark A Harris
Journal:  Toxicol Pathol       Date:  2017-11-21       Impact factor: 1.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.